Myelodysplastic Syndromes (MDS)
Rigosertib in Combination With Azacitidine in Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia: Results of a Phase 1 Study
Phase 1 results from a Phase 1/2 study comprise 18 patients with myelodysplastic syndromes myelodysplastic syndromes: (my-eh-
Iron Overload Alters the Energy Metabolism in Patients With Myelodysplastic Syndromes: Results From the Multicenter FISM BIOFER Study
Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez) A group of disorders where the bone
Myelodysplastic Syndromes: A Review of Therapeutic Progress Over the Past 10 Years
Introduction: Myelodysplastic syndromes Myelodysplastic syndromes: (my-eh-lo-diss-PLASS-tik SIN-dromez)
High Serum Ferritin Levels in Newly Diagnosed Patients With Myelodysplastic Syndromes Are Associated With Greater Symptom Severity
We examined the association between serum ferritin ferritin: (FER-i-tin) A protein inside of cells that stores iron for later use by your body. Sometimes ferritin is released into the blood.
Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients With Myelodysplastic Syndromes: Results of a Large Web-Based Survey
Next-generation sequencing (NGS) is increasingly employed for diagnosis, risk stratification, and management of patients with myelodysplastic syndrome (MDS). We aimed to describe beliefs and practice patterns among providers who treat MDS patients with respect to the utility of NGS in diagnosis, risk stratification, prognosis, and treatment decisions at various points along the disease trajectory, response assessment, and development of institutional guidelines for MDS-specific molecular profiling.
Sarah Bannon, MS, CGC
Institution
University of Texas MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
Pediatric
About
Sarah Bannon is a Senior Genetic Counselor in the Department of Clinical Cancer Genetics at the UT MD Anderson Cancer Center. Her clinical responsibilities include providing risk assessment and genetic counseling services to individuals at risk for an inherited predisposition to hematologic malignancies (leukemia). She is the Genetic Counselor for the Hereditary Hematologic Malignancies Clinic (HHMC).
Mary K. Hughes, MS, RN, CNS, CT
Institution
University of Texas MD Anderson Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Mary K. Hughes, MS, RN, CNS, CT, is a Outpatient, Clinical Nurse Specialist with the University of Texas MD Anderson Cancer Center Psychiatry Department where she works with a team of mental health professionals to support patients, families and caregivers from diagnosis to treatment to survivorship.
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure
Hypomethylating agents (HMAs) are the current standard of care in high-risk myelodysplastic syndromes myelodysplastic syndromes: